Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Axcella Health Inc (AXLA)

Axcella Health Inc (AXLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,173
  • Shares Outstanding, K 52,576
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,630 K
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.90
Trade AXLA with:

Options Overview Details

View History
  • Implied Volatility 221.38% ( -214.64%)
  • Historical Volatility 138.84%
  • IV Percentile 81%
  • IV Rank 22.55%
  • IV High 866.28% on 05/16/22
  • IV Low 33.59% on 02/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 2,289
  • Open Int (30-Day) 2,039

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.32
  • Low Estimate -0.41
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +9.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5400 +4.55%
on 09/26/22
2.7000 -40.37%
on 09/02/22
-0.8100 (-33.47%)
since 08/26/22
3-Month
1.5400 +4.55%
on 09/26/22
2.7400 -41.24%
on 08/17/22
-0.3100 (-16.15%)
since 06/24/22
52-Week
1.3500 +19.26%
on 05/13/22
4.3999 -63.41%
on 10/26/21
-1.4600 (-47.56%)
since 09/24/21

Most Recent Stories

More News
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 1.6100 (-0.62%)
Axcella Reports Second Quarter Financial Results and Provides Business Update

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 1.6100 (-0.62%)
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

AXLA : 1.6100 (-0.62%)
PLRX : 20.30 (+2.37%)
FRLN : 0.7260 (-5.65%)
ABSI : 2.96 (-4.82%)
DICE : 17.46 (-5.93%)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

AXLA : 1.6100 (-0.62%)
PLRX : 20.30 (+2.37%)
FRLN : 0.7260 (-5.65%)
ABSI : 2.96 (-4.82%)
DICE : 17.46 (-5.93%)
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 1.6100 (-0.62%)
Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies....

ALKS : 22.08 (-1.08%)
PRPH : 10.54 (+3.74%)
SESN : 0.3933 (-4.07%)
AXLA : 1.6100 (-0.62%)
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 1.6100 (-0.62%)
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 1.6100 (-0.62%)
Axcella Reports First Quarter Financial Results and Provides Business Update

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 1.6100 (-0.62%)
Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?

Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.

BIIB : 196.58 (-0.61%)
ZSAN : 0.5576 (+7.23%)
AXLA : 1.6100 (-0.62%)
APLT : 0.9285 (-3.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company's principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical...

See More

Key Turning Points

3rd Resistance Point 1.7833
2nd Resistance Point 1.7467
1st Resistance Point 1.6833
Last Price 1.6100
1st Support Level 1.5833
2nd Support Level 1.5467
3rd Support Level 1.4833

See More

52-Week High 4.3999
Fibonacci 61.8% 3.2348
Fibonacci 50% 2.8749
Fibonacci 38.2% 2.5151
Last Price 1.6100
52-Week Low 1.3500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar